Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeutics against SARS-CoV-2 Infection
Viruses · 2024
DOI: 10.3390/v16020273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Debarati Chanda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Pathobiology, Oklahoma State University, Stillwater, OK 74078, USA. Hauptthemen laut MEDLINE: COVID-19, Respiratory Distress Syndrome, Extracellular Vesicles, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Organicell, Oklahoma State University College of Veterinary Medicine.
Abstract (Originalsprache)
The ongoing COVID-19 pandemic caused by SARS-CoV-2 is associated with acute respiratory distress syndrome (ARDS) and fatal pneumonia. Excessive inflammation caused by SARS-CoV-2 is the key driver of ARDS and lethal disease. Several FDA-approved drugs that suppress virus replication are in clinical use. However, despite strong evidence for the role of virus-induced inflammation in severe COVID-19, no effective anti-inflammatory drug is available to control fatal inflammation as well as efficiently clear the virus. Therefore, there is an urgent need to identify biologically derived immunomodulators that suppress inflammation and promote antiviral immunity. In this study, we evaluated acellular human amniotic fluid (acAF) containing extracellular vesicles (hAF-EVs) as a potential non-toxic and safe biologic for immunomodulation during COVID-19. Our in vitro results showed that acAF significantly reduced inflammatory cytokine production in TLR2/4/7 and SARS-CoV-2 structural protein-stimulated mouse macrophages. Importantly, an intraperitoneal administration of acAF reduced morbidity and mortality in SARS-CoV-2-infected mice. A detailed examination of SARS-CoV-2-infected lungs revealed that the increased protection in acAF-treated mice was associated with reduced viral titers and levels of inflammatory myeloid cell infiltration. Collectively, our results identify a novel biologic that has potential to suppress excessive inflammation and enhance survival following SARS-CoV-2 infection, highlighting the translational potential of acAF against COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Pathobiology, Oklahoma State University, Stillwater, OK 74078, USA.
- Organicell Regenerative Medicine, Davie, FL 33314, USA.
ORCID-Profile: Debarati Chanda, Tania Del Rivero, Roshan Ghimire, Maria Ines Mitrani
Förderung
- NIH HHS
- Organicell
- Oklahoma State University College of Veterinary Medicine
Zitieren
APA
Chanda, D., Del Rivero, T., Ghimire, R., More, S., Mitrani, M. I., Bellio, M. A., & Channappanavar, R. (2024). Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeutics against SARS-CoV-2 Infection. Viruses. https://doi.org/10.3390/v16020273
Vancouver
Chanda D, Del Rivero T, Ghimire R, More S, Mitrani MI, Bellio MA, et al. Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeutics against SARS-CoV-2 Infection. Viruses. 2024. doi:10.3390/v16020273
BibTeX
@article{Chanda2024,
author = {Chanda, Debarati and Del Rivero, Tania and Ghimire, Roshan and More, Sunil and Mitrani, Maria Ines and Bellio, Michael A and Channappanavar, Rudragouda},
title = {Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeutics against SARS-CoV-2 Infection},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16020273}
}
EUVIMED